The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Patient experience of early high grade symptomatic adverse events on early phase clinical trials using the PRO-CTCAE.
 
Geoffrey Alan Watson
Honoraria - Pfizer
Travel, Accommodations, Expenses - Abbvie
 
Zachary William Neil Veitch
Honoraria - Genomic Health; Pfizer/EMD Serono
 
Daniel Shepshelovich
No Relationships to Disclose
 
Zhihui (Amy) Liu
No Relationships to Disclose
 
Anna Spreafico
Honoraria - Bristol-Myers Squibb; Janssen Oncology
Consulting or Advisory Role - Bristol-Myers Squibb; Merck; Novartis; Oncorus
Research Funding - Alkermes; Array BioPharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; GlaxoSmithKline; Janssen Oncology; Merck; Northern Biologics; Novartis; Replimune; Roche; Surface Oncology; Symphogen
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; Idera; Janssen Oncology; Merck; Roche
 
Albiruni Ryan Abdul Razak
Consulting or Advisory Role - Adaptimmune; Bayer; Merck
Research Funding - Abbvie; Adaptimmune; Amgen; Blueprint Medicines; Bristol-Myers Squibb; Deciphera; GlaxoSmithKline; Iterion Therapeutics; Karyopharm Therapeutics; MedImmune; Merck; Pfizer; Roche/Genentech
 
Philippe L. Bedard
Consulting or Advisory Role - Amgen; BMS (Inst); Lilly; Merck; Pfizer (Inst); Seagen
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bicara Therapeutics (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Lilly (Inst); Merck (Inst); Mersana (Inst); Nektar (Inst); Novartis (Inst); PTC Therapeutics (Inst); Sanofi (Inst); Seagen (Inst); SERVIER (Inst)
 
Lillian L. Siu
Leadership - Treadwell Therapeutics (I)
Stock and Other Ownership Interests - Agios (I)
Consulting or Advisory Role - Arvinas; AstraZeneca/MedImmune; Daiichi Sankyo/UCB Japan; GlaxoSmithKline; Janpix; Loxo; Merck; Mirati Therapeutics; MorphoSys; Navire; Oncorus; Relay Therapeutics; Roche; Seagen; Symphogen; Treadwell Therapeutics; Voronoi Health Analytics
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVID Radiopharmaceuticals (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Intensity Therapeutics (Inst); Karyopharm Therapeutics (Inst); MedImmune (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Shattuck Labs (Inst); Symphogen (Inst)
 
Lori M. Minasian
No Relationships to Disclose
 
Aaron Richard Hansen
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; GlaxoSmithKline; Merck
Research Funding - Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Boehringer Ingelheim; Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Macrogenics (Inst); Merck (Inst); Roche/Genentech (Inst)